Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Filings indexed 1,022 across all filing types
Latest filing 2017-11-09 Interim / Quarterly Rep…
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report 9M 2017
2017-11-09 English
FORM 4 -
Director's Dealing
2017-08-24 English
FORM 4 -
Director's Dealing
2017-08-23 English
FORM 4 -
Director's Dealing
2017-08-22 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Madrigal Pharmaceuticals, Inc. It specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company issued a press release announcing financial results for the second fiscal quarter ended June 30, 2017. The document includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data itself. The length of the document is 3817 characters, which is relatively short and consistent with a report announcing financial results rather than the full financial report. According to the rules, such a document is classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results with key highlights only, not the full interim or annual report.
2017-08-10 English
10-Q
Interim / Quarterly Report Q2 2017
2017-08-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.